Pharma ‘preparing for major disruptions’ from Trump tariffs

The pharmaceutical industry is preparing for ‘major disruptions’ following US President Donald Trump’s announcement on tariffs, says data and analytics firm GlobalData.

There will be 25% on imports from Canada and Mexico—both paused for 30 days—and 10% on China in tariffs that could worsen drug shortages, raise prices, and push manufacturers to reconsider their market strategies.

The proposed tariffs are expected to impact pharmaceutical foreign direct investment (FDI) by the USA in affected countries, including Europe, GlobalData says.